Outcomes of pregnancy in Egyptian women with multiple sclerosis in the new treatment era: a multi-center retrospective observational study

Table 3 The effect of pregnancy and labor on MS outcomes

Characteristic	Total, n = 116
Pregnancy
Relapse during pregnancy, no. (%)	13 (11.21%)
DMT use during pregnancy^a, no. (%)
Intentionally	6 (5.17%)
Accidentally (at first trimester)	38 (32.76%)
DMT type used (Intentionally)
Interferon-beta	5 (83.33%)
DMT type used (Accidentally)
Interferon-beta	15 (39.47%)
Dimethyl fumarate	7 (18.42%)
Fingolimod	12 (31.58%)
Rituximab	3 (7.89%)
ocrelizumab	1 (2.63%)
Postpartum period
No. of pregnancies with postpartum relapses, no. (%)
0	85 (73.28%)
1	24 (20.69%)
2	5 (4.31%)
≥ 3	2 (1.72%)
Time to first postpartum relapse^b, median (IQR), days	171 (78–232)
DMT use during postpartum year, no. (%)
None	69 (59.48%)
Interferon-beta	22 (18.97%)
Dimethyl fumarate	7 (6.03%)
Natalizumab	3 (2.57%)
Rituximab	4 (3.45)
Fingolimod	8 (6.90%)
Ocrelizumab	3 (2.57%)
Time to restart DMT after delivery^c (median, IQR), d	86 (29–201)

DMT disease-modifying therapy; IQR interquartile range; MS multiple sclerosis
^aDuring the second and/or third trimester
^bOf those who relapse
^cOf those who resumed DMTs